ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients

This study has been completed.

Sponsored by: GMP Endotherapeutics
Information provided by: GMP Endotherapeutics
ClinicalTrials.gov Identifier: NCT00034255
  Purpose

The purpose of this study is to evaluate the safety and tolerability of single and multiple doses of intramuscular INGAP Peptide given for the first time in humans as a potential treatment for diabetes.


Condition Intervention Phase
Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2
Drug: INGAP Peptide
Phase I
Phase II

MedlinePlus related topics:   Diabetes    Diabetes Type 1   

Drug Information available for:   Insulin   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Safety/Efficacy Study
Official Title:   Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients

Further study details as provided by GMP Endotherapeutics:

Estimated Enrollment:   62
Study Start Date:   December 2001

  Eligibility
Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Inclusion Criteria:

Patients meeting all of the following inclusion criteria at screening can be considered for admission to the study.

Stage 1 and Stage 2:

  1. Male and female patients with, type 1 diabetes mellitus that are 18 through 70 years of age, or type 2 diabetes mellitus that are 30 through 70 years of age.
  2. Patients who are insulin deficient and are diagnosed with type 1 or type 2 diabetes mellitus, and are currently well managed with insulin, with or without metformin.
  3. Patients who have been on stable doses of insulin treatment for 90 days prior to study randomization.

Exclusion Criteria:

Patients meeting any of the following exclusion criteria at screening will not be enrolled in the study:

  1. Patients with a history of any clinically significant retinopathy, symptomatic autonomic neuropathy, unstable angina, or kidney problems.
  2. Patients with an uncontrolled or untreated significant pulmonary, neurological condition, or cardiovascular disease, including hypertension, congestive heart failure, angina, or peripheral vascular disease.
  3. Patients who have received any investigational product within 30 days of admission into the study.
  4. Patients with a history or clinical evidence of multiple organ autoimmune disorders.
  5. Patients with a medical condition, serious intercurrent illness, or extenuating circumstance that would significantly decrease study compliance, including all prescribed follow-up.
  6. Patients who are lactating and breastfeeding.
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00034255

Locations
United States, California
VASDHS Medical Center    
      San Diego, California, United States, 92161
United States, District of Columbia
MedStar Research Institute - Clinical Research Center    
      Washington, District of Columbia, United States, 20003
United States, North Carolina
UNC Diabetes, Endocrinology, Metabolism Clinic    
      Durham, North Carolina, United States, 27713
United States, Texas
Texas Diabetes Institute    
      San Antonio, Texas, United States, 78284

Sponsors and Collaborators
GMP Endotherapeutics
  More Information


Study ID Numbers:   INGAP-01-001
First Received:   April 24, 2002
Last Updated:   June 23, 2005
ClinicalTrials.gov Identifier:   NCT00034255
Health Authority:   United States: Food and Drug Administration

Study placed in the following topic categories:
Autoimmune Diseases
Metabolic Diseases
Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2
Diabetes Mellitus
Endocrine System Diseases
Endocrinopathy
Metabolic disorder
Glucose Metabolism Disorders
Insulin

Additional relevant MeSH terms:
Immune System Diseases

ClinicalTrials.gov processed this record on November 20, 2008




Links to all studies - primarily for crawlers